An earlier important study by Pernas et al.39 reported that Gefitinib differentially affected the phosphorylation of Akt, ERK and STAT3 and suggested that Akt and STAT3 were crucial markers and therapeutic targets in HNSCC. The gene discussed is STAT3; the disease is head and neck squamous cell carcinoma.